Andere talen Vaxcyte, Inc.

Aandelen

PCVX

US92243G1085

Geschatte realtime Cboe BZX Andere beurzen 16:00:45 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
60,7 ^USD	-0,54%		-0,39%	-3,44%

25/04	Vaxcyte Insider verkocht aandelen ter waarde van $928.845, volgens een recente SEC filing	MT
22/04	Vaxcyte Insider verkocht aandelen ter waarde van $490.199, volgens een recente SEC filing	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	25/04
Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	22/04
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Certain Pre-Funded Warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing	21/03
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants	04/03
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	04/03
Vaxcyte Q4 Loss Widens	27/02
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	27/02
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024	15/02
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	03/02
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	03/02
Vaxcyte Insider Sold Shares Worth $357,500, According to a Recent SEC Filing	02/02
Vaxcyte to Present at the Guggenheim Healthcare Talks \| 6th Annual Biotechnology Conference	01/02
Vaxcyte Insider Sold Shares Worth $1,980,900, According to a Recent SEC Filing	31/01
Vaxcyte Insider Sold Shares Worth $270,000, According to a Recent SEC Filing	31/01
Vaxcyte Prices $750 Million Public Offering at $64 Per Share	31/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Vaxcyte, Inc.

Aandelen

PCVX

US92243G1085

Andere talen

Filters